[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@BPharmCatalyst "BioPharmCatalyst Weekly #Watchlist Key PDUFA and Regulatory Catalysts for the Next X Months $OMER $ABEO $RGNX $FBIO $CYTK $VNDA $OTLK $IONS $ARWR $TNXP $GRPH"
@BPharmCatalyst on X 2025-07-14 13:17:37 UTC 29.9K followers, 7379 engagements

"BioPharmCatalyst Weekly #Watchlist Key Phase X Catalysts for the Next X Months $ZYNE $PRAX $KPTI $AZN $DBVT $BTAI $AVBP $ABVX $XOMA $ENSC"
@BPharmCatalyst on X 2025-06-30 13:53:24 UTC 29.8K followers, 6357 engagements

"🎧 New Episode Alert On Biotech Bulls and Breakthroughs John Gagliano and Sheff break down: 🔹 Key biotech market trends 🔹 Catalyst-driven trading strategies 🔹 Small-cap opportunities"
@BPharmCatalyst on X 2025-07-14 11:38:00 UTC 29.9K followers, 241.3K engagements

"$GLPG reported that its first quarter 2025 results show consistent revenues of 140.3M but a significant XX% surge in R&D expenses to 278M. Overall expenses (G&A S&M) rose XX% to 74.5M. This led to a net loss of 259.1M a stark contrast to Q1 2024's 99.2M profit. Operating loss widened by XXX% to 215.7M. The company is exploring divestiture of its cell therapy business but maintains strong CAR-T programs and a solid 3.1B cash balance. See More Pre-market Movers 👇 $CYCC $PALI $ANNX $ATHE $MNOV $THAR $PSTV $ATRA $RCKT"
@BPharmCatalyst on X 2025-07-24 12:32:10 UTC 29.9K followers, 4227 engagements

"$ABVX shares are halted following results that its 50mg obefazimod achieved XXXX% pooled placebo-adjusted clinical remission at X weeks in Phase X ABTECT induction trials for moderate-to-severe UC meeting all key secondary endpoints with favorable safety. Maintenance data is due 2Q 2026 ahead of planned NDA/MAA submissions in 2H 2026. The company also delayed 1H 2025 financial results from August XX to September X 2025. Preliminary cash and cash equivalents as of June XX 2025 were approximately $XXXX million (unaudited). See More Biotech Updates👇 $IOVA $REPL $PMN $QNTM $STRO $AMIX $ABVX"
@BPharmCatalyst on X 2025-07-22 20:51:45 UTC 29.9K followers, 4098 engagements

"BioPharmCatalyst Weekly #Watchlist January XX 2024: Key Regulatory Catalysts for the next X months $OPTN $ABEO $GERN $IMGN $IPVA $AKBA $ASND $ESPR $ORTX $IBRX $TEVA"
@BPharmCatalyst on X 2024-01-13 15:21:00 UTC 29.9K followers, 4930 engagements

"$MRK will acquire $VRNA for $XXX per ADS in a deal valued at approximately $XX billion securing full ownership of Veronas respiratory drug assets. See More Pre-market Movers 👇 $KZIA $EVOK $PROK $ARTL $RXST $BCTX $BNTC $RYTM $ZVSA"
@BPharmCatalyst on X 2025-07-09 12:33:08 UTC 29.8K followers, 5773 engagements

"$WINT signed a $60M securities purchase agreement led by Build and Build Corp with the potential to raise a total of $200M to launch a BNB crypto treasury strategy. Subject to shareholder approval Windtree aims to become the first NASDAQ-listed company offering direct BNB token exposure. See More Pre-market Movers 👇 $WINT $SRPT $PRTC $RCKT $NUWE"
@BPharmCatalyst on X 2025-07-17 12:23:48 UTC 29.9K followers, 4379 engagements

"$SONN announced a business combination with Rorschach I LLC to form Hyperliquid Strategies Inc (HSI) a crypto treasury company expected to hold $888M in assets including 12.6M HYPE tokens and $305M in cash. HSI will remain listed on Nasdaq with backing from top crypto investors. See More Pre-market Movers 👇 $RANI $CELC $RARE $PRQR $IPA $EPIX $MGRM"
@BPharmCatalyst on X 2025-07-14 12:23:23 UTC 29.9K followers, 5116 engagements

"$ITOS to be acquired by Concentra Biosciences for $10.047/share in cash plus a CVR tied to net cash above $475M and potential asset sales; tender offer to begin by Aug X 2025. See More Pre-market Movers 👇 $PMN $HSDT $ZIMV $SABS $NCNA $AUTL $EVO"
@BPharmCatalyst on X 2025-07-21 12:20:13 UTC 29.9K followers, 6196 engagements

"$CLSD initiated a strategic review to explore options including asset sales partnerships or M&A to advance its SCS platform; Piper Sandler retained to lead the process. See More Biotech Updates👇 $WINT $SRPT $RCKT $FOLD $MBRX $CLSD $ICU"
@BPharmCatalyst on X 2025-07-17 20:25:54 UTC 29.8K followers, 5561 engagements

"$ANGO issued FY2026 guidance with projected net sales of $305310M slightly above the $304.9M consensus. Adjusted EPS is expected to show a loss of $0.350.25 vs. a $XXXX loss consensus with the forecast reflecting a $46M tariff headwind based on current July 2025 trade policy expectations. See More Pre-market Movers 👇 $SXTP $ADAG $OSTX $SLS $PMN"
@BPharmCatalyst on X 2025-07-15 12:27:21 UTC 29.9K followers, 4812 engagements

"Want more info analysis and biotech news straight to your inbox Sign up for our FREE Daily and Weekly newsletters here:"
@BPharmCatalyst on X 2025-07-16 21:44:57 UTC 29.9K followers, 1416 engagements

"BioPharmCatalyst Weekly #Watchlist Key PDUFA and Regulatory Catalysts for the Next X Months $OMER $ABEO $RGNX $FBIO $CYTK $VNDA $OTLK $IONS $ARWR $TNXP $GRPH"
@BPharmCatalyst on X 2025-07-12 13:18:12 UTC 29.9K followers, 7306 engagements

"Biotech updates 08/23: $GSK +ve anti-BCMA multiple myeloma data $EPIX offering +26% $SEEL offering -XX% $TENX data 1Q 2020 +6% $HEB - $AIM Pipeline updates $INCY $ZSAN"
@BPharmCatalyst on X 2019-08-23 23:55:00 UTC 29.8K followers, XX engagements

"$PMN shares closed up after the company announced that PMN310 its lead therapeutic candidate for Alzheimer's received FDA Fast Track designation. See More Biotech Updates👇 $PMN $ZIMV $EVO $SABS $HOOK $SLRX $CLSD $GDTC"
@BPharmCatalyst on X 2025-07-21 20:58:48 UTC 29.9K followers, 2395 engagements

"Biotech updates 07/10: $AMRX lowers profit forecast -XX% $OHRP holders approve merger +15% $SNSS offering -XX% $EYEN offering -XX% (-6% AH) $NBIX opicapone PDUFA 4/26/20 $SNY Isatuximab PDUFA 4/30/20 Pipeline updates $GSK $HZNP $LGND $MRK $SNDX"
@BPharmCatalyst on X 2019-07-10 21:06:52 UTC 29.8K followers, XX engagements

"BioPharmCatalyst updates 06/21/21: $TARS eyelash mite infestation data -XX% $ARWR collab +5% $CTXR +15%; $AVXL +14%; $SAVA +13% $NTEC -17%; $APVO -14%; $MLND -XX% Pipeline updates $AGIO $ANEB $AVXL $IMMP $INBX $MBRX $NXTC $OYST $RGLS $SRRA $TBPH $TNXP"
@BPharmCatalyst on X 2021-06-21 21:38:52 UTC 29.9K followers, XX engagements

"BioPharmCatalyst updates 02/25/21: $PAND acquired by MRK +133% $SRPT FDA Approval $ASLN private placement +27% $NVCR trial delays -XX% $TCDA -XX% AH Pipeline updates $AKBA $ASLN $ASMB $CARA $CMRX $EIDX $GKOS $ICPT $NVCR $REGN $YMAB $ZGNX"
@BPharmCatalyst on X 2021-02-25 23:49:48 UTC 29.9K followers, XX engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX"
@BPharmCatalyst on X 2025-07-19 15:00:00 UTC 29.9K followers, 6965 engagements

"Biotech updates 08/02: $GLYC fail -XX% AH $ACOR earnings -XX% $STML earnings +14% $CHRS earnings +18% $OASM leaving NASDAQ Pipeline updates $DCPH $IMGN $MNTA"
@BPharmCatalyst on X 2019-08-02 23:39:04 UTC 29.9K followers, XX engagements

"$TELO reported promising data for Telomir-1 which showed it could reverse epigenetic gene silencing and restore tumor suppressors in human prostate cancer cells outperforming chemotherapy and rapamycin. See More Pre-market Movers 👇 $MESO $CNSP $SRPT $WINT $IINN"
@BPharmCatalyst on X 2025-07-18 12:20:59 UTC 29.9K followers, 2537 engagements

"$MIST received a new PDUFA date of Dec XX 2025 for CARDAMYST nasal spray for PSVT after FDA accepted its CRL resubmission. The company also extended its $75M royalty deal with RTW through year-end. Separately Milestone priced a $52.5M public offering of common and pre-funded warrants at $1.50/share expected to close July XX 2025. See More Biotech Updates👇 $NCNA $INKT $MIST $CAPR $JUNS $PHVS $DARE"
@BPharmCatalyst on X 2025-07-11 20:16:19 UTC 29.8K followers, 6185 engagements